Polyrizon (PLRZ) Competitors $1.04 -0.04 (-3.26%) As of 02/21/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends PLRZ vs. MEIP, ATHA, MRKR, SPRB, SLGL, GLYC, GOVX, AFMD, SYBX, and NRSNShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include MEI Pharma (MEIP), Athira Pharma (ATHA), Marker Therapeutics (MRKR), Spruce Biosciences (SPRB), Sol-Gel Technologies (SLGL), GlycoMimetics (GLYC), GeoVax Labs (GOVX), Affimed (AFMD), Synlogic (SYBX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. MEI Pharma Athira Pharma Marker Therapeutics Spruce Biosciences Sol-Gel Technologies GlycoMimetics GeoVax Labs Affimed Synlogic NeuroSense Therapeutics MEI Pharma (NASDAQ:MEIP) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends. Which has stronger earnings and valuation, MEIP or PLRZ? MEI Pharma has higher revenue and earnings than Polyrizon. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMEI Pharma$65.30M0.27$17.78M-$5.73-0.45PolyrizonN/AN/AN/AN/AN/A Do analysts rate MEIP or PLRZ? MEI Pharma currently has a consensus price target of $7.00, suggesting a potential upside of 168.71%. Given MEI Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe MEI Pharma is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MEI Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Polyrizon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of MEIP or PLRZ? 52.4% of MEI Pharma shares are held by institutional investors. 3.1% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor MEIP or PLRZ? MEI Pharma received 412 more outperform votes than Polyrizon when rated by MarketBeat users. CompanyUnderperformOutperformMEI PharmaOutperform Votes41262.71% Underperform Votes24537.29% PolyrizonN/AN/A Is MEIP or PLRZ more profitable? Polyrizon's return on equity of 0.00% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets MEI PharmaN/A -84.92% -67.53% Polyrizon N/A N/A N/A Does the media prefer MEIP or PLRZ? In the previous week, MEI Pharma had 1 more articles in the media than Polyrizon. MarketBeat recorded 1 mentions for MEI Pharma and 0 mentions for Polyrizon. MEI Pharma's average media sentiment score of 0.00 equaled Polyrizon'saverage media sentiment score. Company Overall Sentiment MEI Pharma Neutral Polyrizon Neutral SummaryMEI Pharma beats Polyrizon on 7 of the 9 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.51M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / BookN/A6.717.644.62Net IncomeN/A$138.55M$3.19B$245.94M7 Day Performance-7.67%-2.63%-2.11%-2.62%1 Month Performance-29.73%-2.33%-0.49%-2.15%1 Year PerformanceN/A-5.33%16.44%12.95% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$1.04-3.3%N/AN/A$4.51MN/A0.00N/AGap DownMEIPMEI Pharma4.1543 of 5 stars$2.66-1.5%$7.00+163.2%-41.1%$17.72M$65.30M-0.38100Analyst ForecastGap DownATHAAthira Pharma2.9125 of 5 stars$0.45-0.7%$13.83+2,980.9%-88.3%$17.36MN/A-0.1640MRKRMarker Therapeutics4.3474 of 5 stars$1.59+2.6%$19.00+1,095.0%-59.9%$17.03M$3.31M0.0060SPRBSpruce Biosciences3.5026 of 5 stars$0.41+1.8%$3.90+850.3%-91.9%$16.95M$10.09M-0.4420Gap UpSLGLSol-Gel Technologies2.6005 of 5 stars$0.60-3.5%$5.00+729.2%-47.7%$16.80M$1.55M-1.7750Gap DownGLYCGlycoMimetics4.1636 of 5 stars$0.26-5.9%$8.00+2,979.3%-90.1%$16.75M$10,000.000.0050Analyst ForecastNews CoverageGap DownGOVXGeoVax Labs1.7314 of 5 stars$1.73+10.2%$14.20+720.8%-24.9%$16.33M$80,000.000.0010AFMDAffimed4.0731 of 5 stars$1.00-4.0%$13.50+1,252.2%-80.2%$16.07M$8.95M0.00200SYBXSynlogicN/A$1.36+1.5%N/A-29.7%$15.91M$3.37M-0.3380NRSNNeuroSense Therapeutics1.1798 of 5 stars$1.16+0.6%N/A-12.8%$15.82MN/A-1.8110 Related Companies and Tools Related Companies MEI Pharma Alternatives Athira Pharma Alternatives Marker Therapeutics Alternatives Spruce Biosciences Alternatives Sol-Gel Technologies Alternatives GlycoMimetics Alternatives GeoVax Labs Alternatives Affimed Alternatives Synlogic Alternatives NeuroSense Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PLRZ) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
